MetaCap

Allarity Therapeutics Inc. (ALLR)

NASDAQ: ALLRHealth CareBiotechnology: Pharmaceutical PreparationsUSD

0.785-0.08 (-9.25%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

ALLR stock chart

Technical analysis

Key statistics

All statistics
Market cap
$12.56M
EPS (TTM)
-$0.79
52-week range
0.769 – 1.84
Day range
0.78 – 0.8905
Volume / Avg
305.15K / 131.74K
Beta
—

52-week range

$0.769$1.84

ALLR stock today

Shares of Allarity Therapeutics (ALLR) finished lower on Nov 20 at $0.785, a drop of 9.25% or $0.08 per share, versus the S&P 500's 3.70% decline. Volume was 2.3x the average at 305.15K shares, a sign of unusually heavy trading. Shares are 57.3% below their 52-week high of $1.84, set on May 27, 2026 and 2.1% above the 52-week low of $0.769, near the bottom of the past year's range.

ALLR is down 27.3% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 25.9%. Allarity Therapeutics has posted a net loss over the last twelve months (EPS of -$0.79), so its P/E ratio is not meaningful.

Summary generated from market data by MetaCap's automated system. Methodology

About Allarity Therapeutics

Company profile

Allarity Therapeutics, Inc., a clinical-stage precision medicine pharmaceutical company, focuses on developing anti-cancer therapeutics for patients with unmet medical needs in Denmark and the United States. The company develops drugs for the personalized treatment of cancer using drug-specific companion diagnostics generated by its proprietary drug response predictor (DRP) technology. Its lead drug candidate is stenoparib, a dual inhibitor of poly-ADP-ribose polymerase (PARP1/2), which is in a Phase 2 clinical trial for patients with advanced and recurrent ovarian cancer.

Industry
Biotechnology: Pharmaceutical Preparations
CEO
Mr. Thomas H. Jensen
Headquarters
Tarpon Springs, FL
Employees
7

Financial highlights

Full financials

In fiscal 2025, Allarity Therapeutics generated $320,000 in revenue, up 0.0% from fiscal 2024. Allarity Therapeutics reported a net loss of $11.2 million, compared with a loss of $24.5 million a year earlier. Operating margin was -3939.1%.

Allarity Therapeutics annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021
Revenue$320.00K$0———
Growth—————
Net income$-11.23M$-24.52M$-11.90M$-16.06M$-26.65M
EPS (diluted)——$-10.26$-3,093.42$-4.19

Analyst forecast

Forecast

Consensus (1 analysts)

none

Avg. price target

$11.00+1301.27%

  • Strong buy 0
  • Buy 1
  • Hold 0
  • Sell 0
  • Strong sell 0

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Nov 13, 2026
EPS actual vs est.
$-0.39 vs $-0.21
Surprise
-85.71%

ALLR news

All ALLR news

Allarity Therapeutics peers

Health Care sector
ALLR peer companies
CompanyPrice% ChgMarket capCompare
MCRBSeres Therapeutics Inc.1.24-6.77%$12.64Mvs ALLR
NEUPNeuphoria Therapeutics Inc.2.35+1.29%$12.72Mvs ALLR
BOLTBolt Biotherapeutics Inc.4.91-2.96%$12.80Mvs ALLR
MIRAMIRA Pharmaceuticals Inc.0.291-20.84%$12.23Mvs ALLR
TVRDTvardi Therapeutics Inc.0.9893+4.57%$13.22Mvs ALLR
ACTUActuate Therapeutics Inc.0.2253+5.38%$13.60Mvs ALLR
BYSIBeyondSpring Inc.0.33-24.49%$13.66Mvs ALLR
CTXRCitius Pharmaceuticals Inc.0.5085+2.27%$13.96Mvs ALLR

Indexes, lists and sector

Allarity Therapeutics stock FAQ

What is Allarity Therapeutics's stock price today?

ALLR last traded at $0.785 as of Nov 20, 4:00 PM EST, down 9.25% on the day. Prices are delayed at least 15 minutes.

Does Allarity Therapeutics pay a dividend?

No. Allarity Therapeutics does not currently pay a regular cash dividend.

Who is Allarity Therapeutics's CEO?

Mr. Thomas H. Jensen is the chief executive officer of Allarity Therapeutics Inc., which has about 7 employees.

Has ALLR ever split its stock?

Yes. The most recent ALLR stock split was a 1-for-30 split on Sep 11, 2024, one of 4 splits on record.

What is the ALLR 52-week high?

The 52-week high for ALLR is $1.84 and the 52-week low is $0.769. The stock is currently 57.3% below its high.

Compare ALLR